JPS52136172A - Polypeptide* its preparation and medical and veterinary compositions having rulibeline synergistic effect - Google Patents

Polypeptide* its preparation and medical and veterinary compositions having rulibeline synergistic effect

Info

Publication number
JPS52136172A
JPS52136172A JP5418677A JP5418677A JPS52136172A JP S52136172 A JPS52136172 A JP S52136172A JP 5418677 A JP5418677 A JP 5418677A JP 5418677 A JP5418677 A JP 5418677A JP S52136172 A JPS52136172 A JP S52136172A
Authority
JP
Japan
Prior art keywords
rulibeline
polypeptide
medical
preparation
synergistic effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP5418677A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6113480B2 (cg-RX-API-DMAC10.html
Inventor
Suwaruupu Doutsuta Anando
Jiyon Arubaato Fuaa Baarinton
Buraian Jiyairuzu Maikuru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Chemical Industries Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Publication of JPS52136172A publication Critical patent/JPS52136172A/ja
Publication of JPS6113480B2 publication Critical patent/JPS6113480B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Plant Substances (AREA)
JP5418677A 1976-05-11 1977-05-11 Polypeptide* its preparation and medical and veterinary compositions having rulibeline synergistic effect Granted JPS52136172A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB19327/76A GB1524747A (en) 1976-05-11 1976-05-11 Polypeptide

Publications (2)

Publication Number Publication Date
JPS52136172A true JPS52136172A (en) 1977-11-14
JPS6113480B2 JPS6113480B2 (cg-RX-API-DMAC10.html) 1986-04-14

Family

ID=10127509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5418677A Granted JPS52136172A (en) 1976-05-11 1977-05-11 Polypeptide* its preparation and medical and veterinary compositions having rulibeline synergistic effect

Country Status (27)

Country Link
US (1) US4100274A (cg-RX-API-DMAC10.html)
JP (1) JPS52136172A (cg-RX-API-DMAC10.html)
AT (2) AT379400B (cg-RX-API-DMAC10.html)
AU (1) AU508025B2 (cg-RX-API-DMAC10.html)
BE (1) BE854467A (cg-RX-API-DMAC10.html)
BG (1) BG60740B2 (cg-RX-API-DMAC10.html)
CA (1) CA1101844A (cg-RX-API-DMAC10.html)
CH (2) CH627151A5 (cg-RX-API-DMAC10.html)
CS (1) CS199673B2 (cg-RX-API-DMAC10.html)
DD (1) DD136738A5 (cg-RX-API-DMAC10.html)
DE (1) DE2720245C2 (cg-RX-API-DMAC10.html)
DK (1) DK149596C (cg-RX-API-DMAC10.html)
ES (1) ES458691A1 (cg-RX-API-DMAC10.html)
FI (1) FI64139C (cg-RX-API-DMAC10.html)
FR (1) FR2351092A1 (cg-RX-API-DMAC10.html)
GB (1) GB1524747A (cg-RX-API-DMAC10.html)
HU (1) HU179990B (cg-RX-API-DMAC10.html)
IE (1) IE44426B1 (cg-RX-API-DMAC10.html)
IL (1) IL52014A (cg-RX-API-DMAC10.html)
NL (2) NL191793C (cg-RX-API-DMAC10.html)
NO (2) NO147304C (cg-RX-API-DMAC10.html)
NZ (1) NZ183931A (cg-RX-API-DMAC10.html)
PL (2) PL108860B1 (cg-RX-API-DMAC10.html)
SE (2) SE437837B (cg-RX-API-DMAC10.html)
SU (1) SU910116A3 (cg-RX-API-DMAC10.html)
YU (1) YU40672B (cg-RX-API-DMAC10.html)
ZA (1) ZA772433B (cg-RX-API-DMAC10.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55164663A (en) * 1979-06-11 1980-12-22 Syntex Inc Nonapeptide and decapeptide derivatives of progesterone release hormone and its manufacture
EP0779072A1 (en) 1995-12-15 1997-06-18 Takeda Chemical Industries, Ltd. Production of microspheres
EP0781548A2 (en) 1995-12-15 1997-07-02 Takeda Chemical Industries, Ltd. Production of sustained-release preparation for injection
JP2672677B2 (ja) * 1989-02-09 1997-11-05 タツプ・フアーマシユーテイカルズ・インコーポレイテツド Ｌｈｒｈ同族体
WO2003041739A1 (fr) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Agents anticancer
JP2009227687A (ja) * 2004-06-25 2009-10-08 Takeda Chem Ind Ltd メタスチン誘導体およびその用途

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3411224A1 (de) * 1984-03-27 1985-10-10 Hoechst Ag, 6230 Frankfurt Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4705778A (en) * 1985-10-22 1987-11-10 Sri International Orally active LHRH analogs
JPH0284272U (cg-RX-API-DMAC10.html) * 1988-12-20 1990-06-29
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
ES2077675T3 (es) * 1989-03-10 1995-12-01 Endorecherche Inc Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos.
DE69034035T2 (de) * 1989-07-07 2004-01-22 Endorecherche Inc., Ste-Foy Methode zur behandlung androgenbedingter krankheiten
AU5856090A (en) * 1989-07-07 1991-02-06 Endorecherche Inc. Androgen derivatives for use in the inhibition of sex steroid activity
GB9112859D0 (en) * 1991-06-14 1991-07-31 Ici Plc Peptide process
CA2136304A1 (en) * 1992-05-21 1993-11-25 Fernand Labrie Inhibitors of testosterone 5.alpha.-reductase activity
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6448031B1 (en) 1996-06-13 2002-09-10 Itoham Foods Inc. Process for producing LH-RH derivatives
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
US6242421B1 (en) 1997-11-06 2001-06-05 Richard Lloyd Bowen Methods for preventing and treating Alzheimer's disease
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
ES2154590B1 (es) 1999-05-20 2001-11-01 Lipotec Sa Procedimiento de sintesis de peptidos en fase solida
AR023940A1 (es) 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
DE10032256C2 (de) * 2000-07-03 2003-06-05 Infineon Technologies Ag Chip-ID-Register-Anordnung
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
EP1363627A2 (en) 2001-02-19 2003-11-26 Novartis AG Treatment of solid tumours with rapamycin derivatives
US20040167134A1 (en) 2001-05-16 2004-08-26 Christian Bruns Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003240655B2 (en) 2002-05-16 2007-09-06 Novartis Ag Use of EDG receptor binding agents in cancer
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
PT2218448E (pt) 2002-12-13 2016-01-26 Durect Corp Sistema oral de entrega de fármaco que compreende materiais transportadores líquidos de alta viscosidade
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
BRPI0509721A (pt) 2004-04-07 2007-09-25 Novartis Ag inibidores de iap
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP3103477A1 (en) * 2004-09-17 2016-12-14 Durect Corporation Sustained local anesthetic composition containing saib
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
ES2552338T3 (es) 2005-01-21 2015-11-27 Astex Therapeutics Limited Compuestos farmacéuticos
RU2436575C2 (ru) * 2005-01-21 2011-12-20 Астекс Терапьютикс Лимитед Соединения для использования в фармацевтике
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
ES2336826T3 (es) 2005-05-03 2010-04-16 Novetide, Ltd. Procedimientos para la produccion de un peptido que presenta una amida c-terminal.
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
KR20080054417A (ko) 2005-09-27 2008-06-17 노파르티스 아게 카르복시아민 화합물 및 ｈｄａｃ 의존성 질환의 치료에있어서의 그의 용도
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
MX2008014292A (es) 2006-05-09 2008-11-18 Novartis Ag Combinacion que comprende un quelante de hierro y un agente anti-neoplastico, y uso de la misma.
EP2081933B1 (en) 2006-09-29 2011-03-23 Novartis AG Pyrazolopyrimidines as pi3k lipid kinase inhibitors
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
DK2117521T3 (da) 2006-11-03 2012-09-03 Durect Corp Transdermale indgivelsessystemer omfattende bupivacain
CA2677651A1 (en) 2007-02-15 2008-08-21 Novartis Ag Combinations of therapeutic agents for treating cancer
EP2219622A1 (en) * 2007-12-06 2010-08-25 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
KR101673621B1 (ko) 2008-03-24 2016-11-07 노파르티스 아게 아릴술폰아미드-계 매트릭스 메탈로프로테아제 억제제
ES2519474T3 (es) 2008-03-26 2014-11-07 Novartis Ag Inhibidores de las desacetilasas B basados en hidroxamato
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
AU2009319048B2 (en) * 2008-11-28 2014-01-30 Novartis Ag Pharmaceutical combination comprising a Hsp 90 inhibitor and a mTOR inhibitor
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
KR101360725B1 (ko) 2009-06-26 2014-02-07 노파르티스 아게 Ｃｙｐ17의 억제제로서의 1,3-이치환된 이미다졸리딘-2-온 유도체
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
EA201200318A1 (ru) 2009-08-20 2012-09-28 Новартис Аг Гетероциклические оксимы
JP2013503129A (ja) 2009-08-26 2013-01-31 ノバルティス アーゲー テトラ−置換ヘテロアリール化合物ならびにｍｄｍ２および／またはｍｄｍ４モジュレーターとしてのそれらの使用
AU2010294209A1 (en) 2009-09-10 2012-03-29 Irm Llc Ether derivatives of bicyclic heteroaryls
EP2496575B1 (en) 2009-11-04 2014-04-30 Novartis AG Heterocyclic sulfonamide derivatives useful as mek inhibitors
CN102712648A (zh) 2009-11-25 2012-10-03 诺瓦提斯公司 双环杂芳基的与苯稠合的6元含氧杂环衍生物
ES2484171T3 (es) 2009-12-08 2014-08-11 Novartis Ag Derivados de sulfonamidas heterocíclicas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
JP2013528626A (ja) 2010-06-16 2013-07-11 アンドルシェルシュ・インコーポレイテッド エストロゲン関連疾患を治療するまたは予防するための方法
JP2013532149A (ja) 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
CN102947274A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
CN103492390A (zh) 2011-03-08 2014-01-01 诺瓦提斯公司 氟苯基双环杂芳基化合物
WO2012149413A1 (en) 2011-04-28 2012-11-01 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
KR20140045411A (ko) 2011-05-16 2014-04-16 젠자임 코포레이션 Ｃｘｃｒ４ 길항제의 용도
KR20140034898A (ko) 2011-06-09 2014-03-20 노파르티스 아게 헤테로시클릭 술폰아미드 유도체
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
EP2721007B1 (en) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl isoquinolinone compounds
SG195067A1 (en) 2011-06-27 2013-12-30 Novartis Ag Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
EP2785717B1 (en) 2011-11-29 2016-01-13 Novartis AG Pyrazolopyrrolidine compounds
LT2794600T (lt) 2011-12-22 2018-02-26 Novartis Ag 2,3-dihidro-benzo[1,4]oksazino dariniai ir giminingi junginiai kaip fosfoinozitido-3 kinazės (pi3k) inhibitoriai, skirti gydymui, pavyzdžiui, reumatoidinio artrito
WO2013093850A1 (en) 2011-12-22 2013-06-27 Novartis Ag Quinoline derivatives
US20140357633A1 (en) 2011-12-23 2014-12-04 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
KR20140104047A (ko) 2011-12-23 2014-08-27 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
EA201491268A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию
EA201491259A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания
EA201491265A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
US20130310387A1 (en) 2012-05-16 2013-11-21 Novartis Ag Monocyclic Heteroaryl Cycloalkyldiamine Derivatives
WO2013175417A1 (en) 2012-05-24 2013-11-28 Novartis Ag Pyrrolopyrrolidinone compounds
US9789193B2 (en) 2012-06-15 2017-10-17 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
IN2015DN00950A (cg-RX-API-DMAC10.html) 2012-08-13 2015-06-12 Novartis Ag
PL3023415T3 (pl) 2012-10-02 2018-06-29 Gilead Sciences, Inc. Inhibitory demetylaz histonowych
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
BR112015020650A2 (pt) 2013-02-27 2017-07-18 Epitherapeutics Aps inibidores de histona demetilases
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
AU2014321419B2 (en) 2013-09-22 2017-06-15 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
KR20160101027A (ko) 2014-01-15 2016-08-24 노파르티스 아게 제약 조합물
EP3122729A4 (en) 2014-03-28 2017-11-15 Calitor Sciences, LLC Substituted heteroaryl compounds and methods of use
CA2943824A1 (en) 2014-03-31 2015-10-08 Gilead Sciences, Inc. Inhibitors of histone demethylases
RU2016140160A (ru) 2014-04-03 2018-05-07 Инвиктус Онколоджи Пвт. Лтд. Супрамолекулярные комбинаторные лекарственные средства
BR112017003442A2 (pt) 2014-08-27 2017-11-28 Gilead Sciences Inc compostos e métodos para inibir histona desmetilases
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
CN109475505A (zh) 2016-07-06 2019-03-15 度瑞公司 具有药物组成物、屏障层及药物层的口服剂型
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
JP7021356B2 (ja) 2017-12-21 2022-02-16 ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ ピリミジン誘導体系キナーゼ阻害剤類
US10751339B2 (en) 2018-01-20 2020-08-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
CA3155594C (en) * 2019-09-26 2025-06-17 S.I.S. Shulov Innovative Science Ltd. Topical anti-aging compositions containing a tetrapeptide
EP4058465A1 (en) 2019-11-14 2022-09-21 Cohbar Inc. Cxcr4 antagonist peptides
JP2023515918A (ja) 2020-01-13 2023-04-17 デュレクト コーポレーション 不純物が低減された徐放性薬物送達システム及び関連の方法
JP2024503402A (ja) 2021-01-12 2024-01-25 デュレクト コーポレーション 徐放性薬物送達システム及び関連の方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005063A (en) * 1973-10-11 1977-01-25 Abbott Laboratories [Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity
US3914412A (en) * 1973-10-11 1975-10-21 Abbott Lab {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity
US3901872A (en) * 1974-03-13 1975-08-26 American Home Prod P-glu-his-trp-ser-tyr-d-pgl-leu-arg-pro-gly-nh' 2 'and intermediates
JPS50142563A (cg-RX-API-DMAC10.html) * 1974-04-26 1975-11-17
US3896104A (en) * 1974-05-22 1975-07-22 American Home Prod P-glu-his-trp-ser-tyr-d-lys-leu-arg-pro-gly-nh' 2 'and intermediates
DE2438350C3 (de) * 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US3971737A (en) * 1975-03-24 1976-07-27 American Home Products Corporation [2-Methyl-Ala6 ]LRH
US4024121A (en) * 1976-01-27 1977-05-17 Schally Andrew Victor (Pyro)-Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHR and intermediates
US4018726A (en) * 1975-06-12 1977-04-19 Andrew Victor Schally [D-Phe6 ]-LH-RH and intermediates therefor
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US3992530A (en) * 1975-12-08 1976-11-16 American Home Products Corporation [D-2-(1,4-Cyclohexadienyl)gly]6 -des-gly10 -lrh nonapeptide amides

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55164663A (en) * 1979-06-11 1980-12-22 Syntex Inc Nonapeptide and decapeptide derivatives of progesterone release hormone and its manufacture
JPS63264498A (ja) * 1979-06-11 1988-11-01 シンテックス（ユー．エス．エー．）インコーポレイティド 黄体形成ホルモン放出ホルモンのノナペプチド及びデカペプチド誘導体
JP2672677B2 (ja) * 1989-02-09 1997-11-05 タツプ・フアーマシユーテイカルズ・インコーポレイテツド Ｌｈｒｈ同族体
EP0779072A1 (en) 1995-12-15 1997-06-18 Takeda Chemical Industries, Ltd. Production of microspheres
EP0781548A2 (en) 1995-12-15 1997-07-02 Takeda Chemical Industries, Ltd. Production of sustained-release preparation for injection
WO2003041739A1 (fr) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Agents anticancer
JP2009227687A (ja) * 2004-06-25 2009-10-08 Takeda Chem Ind Ltd メタスチン誘導体およびその用途

Also Published As

Publication number Publication date
PL104362B1 (pl) 1979-08-31
FI64139C (fi) 1983-10-10
SE437993B (sv) 1985-03-25
IE44426L (en) 1977-11-11
ATA335877A (de) 1985-05-15
AT365562B (de) 1982-01-25
NO147304B (no) 1982-12-06
IL52014A0 (en) 1977-07-31
NO149586C (no) 1984-05-16
NL970002I2 (nl) 1997-05-01
DD136738A5 (de) 1979-07-25
FI771480A7 (cg-RX-API-DMAC10.html) 1977-11-12
NL7705130A (nl) 1977-11-15
BG60740B2 (bg) 1996-01-31
SE437837B (sv) 1985-03-18
CS199673B2 (en) 1980-07-31
NL191793C (nl) 1996-08-02
AT379400B (de) 1985-12-27
NZ183931A (en) 1979-03-16
CH629475A5 (de) 1982-04-30
ZA772433B (en) 1978-03-29
PL197889A1 (pl) 1978-02-13
CA1101844A (en) 1981-05-26
BE854467A (fr) 1977-11-10
DE2720245C2 (de) 1986-09-25
NO771644L (no) 1977-11-14
IE44426B1 (en) 1981-11-18
NL970002I1 (nl) 1997-03-03
FI64139B (fi) 1983-06-30
US4100274A (en) 1978-07-11
DE2720245A1 (de) 1977-11-24
FR2351092A1 (fr) 1977-12-09
DK149596C (da) 1987-01-05
YU117277A (en) 1983-02-28
NO149586B (no) 1984-02-06
SE8007763L (sv) 1980-11-05
HU179990B (en) 1983-01-28
NO822984L (no) 1977-11-14
IL52014A (en) 1979-11-30
AU2468177A (en) 1978-11-02
JPS6113480B2 (cg-RX-API-DMAC10.html) 1986-04-14
ATA217979A (de) 1981-06-15
PL108860B1 (en) 1980-05-31
GB1524747A (en) 1978-09-13
NL191793B (nl) 1996-04-01
FR2351092B1 (cg-RX-API-DMAC10.html) 1980-02-22
YU40672B (en) 1986-04-30
SE7705432L (sv) 1977-11-12
AU508025B2 (en) 1980-03-06
DK207977A (da) 1977-11-12
SU910116A3 (ru) 1982-02-28
NO147304C (no) 1983-03-16
CH627151A5 (cg-RX-API-DMAC10.html) 1981-12-31
DK149596B (da) 1986-08-04
ES458691A1 (es) 1978-08-16

Similar Documents

Publication Publication Date Title
JPS52136172A (en) Polypeptide* its preparation and medical and veterinary compositions having rulibeline synergistic effect
JPS5318557A (en) Novel aminoalkylfuran derivatives* their preparation and medical composition containing same
IL51660A0 (en) Hentriakontapeptides their preparation and pharmaceutical compositions containing them
JPS51115910A (en) Gradually releaseetype medical composition and its preparation
NZ185986A (en) 2-oxa-bicyclic prostag-landins and pharmaceutical compositions
NZ188173A (en) 7-arylmalonamido-7 a-methoxy-3-(optionally alkylated-thiadiazol-2-yl) thiomethyl-1-oxadethiacephalosporins preparation and pharmaceutical and veterinary compositions
NZ183551A (en) Aminochromanols and pharmaceutical compositions containingthem
ZA752957B (en) Insecticidal compositions and use
JPS5297921A (en) Aralkylaniline derivative* preparation thereof and medical composition containing same
NZ183134A (en) I-i-(3-aryloxy-2-hydroxypropyl)-4-piperidyl-3-aryl-imid-azolidin or hexahydropyrimidin-2-ones; and pharmaceutical compositions
NZ184428A (en) N-acyl-l-alanyl-aminoacyl-amides untermediates and pharmaceutical compositions
JPS5386038A (en) Pharmaceutical composition for animal and application
JPS549282A (en) Novel aminopiperidines*its preparation*and medical compositions
NZ184766A (en) Alkylphenyl ethers and thioethers and pharmaceutical compositions
JPS5323938A (en) Peptide having psychoopharmacologcal activity* its derivative* composition containing same and preparation thereof
JPS5416402A (en) Peptide and medical composition containing same
NZ184912A (en) 2-phenylamino-imidazolines and pharmaceutical compositions
NZ184263A (en) N-(amino-alkyl-amino)-benzamides and pharmaceutical compositions
JPS5312851A (en) Novel phenoxyhydroxypropylamine* its preparation and its application for medical treatment
JPS5346972A (en) Polypeptide* its preparation and pharmaceutical* veterinary composition having rulibeline antagonism
NZ184735A (en) Peptides and pharmaceutical compositions
JPS52102279A (en) And its preparation and medical composition containing same
NZ183549A (en) Amidinopencillanoyloxy-alkyl-amoxycillinates and pharmaceutical compositions
ZA77271B (en) Therapeutic compositions and use thereof
JPS5321160A (en) Novel 55thiazolealkylamine derivative* its preparation and medical composition